Harvard Bioscience (HBIO) Retained Earnings (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Retained Earnings data on file, last reported at -$218.1 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 4.7% year-over-year to -$218.1 million in Q1 2026; TTM through Mar 2026 was -$218.1 million, a 4.7% decrease from a year earlier, with the FY2025 full-year figure at -$214.7 million, down 1270.2% from the prior year.
• Retained Earnings for Q1 2026 stood at -$218.1 million, down from -$214.7 million in the prior quarter.
• Over the last five years, Retained Earnings for HBIO reached as high as -$10.7 million in Q1 2022 and fell as low as -$218.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$99.5 million across 5 years, with a median of -$140.5 million in 2022.
• On a YoY basis, Retained Earnings climbed as much as 92.13% in 2025 and fell as far as 1316.68% in 2025.
• Year by year, Retained Earnings stood at -$15.1 million in 2022, then slumped by 867.35% to -$145.6 million in 2023, then soared by 89.24% to -$15.7 million in 2024, then tumbled by 1270.2% to -$214.7 million in 2025, then declined by 1.59% to -$218.1 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$218.1 million in Q1 2026, -$214.7 million in Q4 2025, and -$12.4 million in Q3 2025.